Aligos Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Aligos Therapeutics

02/11/2023 23:18

* Aligos Therapeutics Inc  ALGS.OQ  reported a quarterly
adjusted
loss of 41 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of -44 cents.  The mean expectation of two analysts
for the quarter was for a loss of 47 cents per share. Wall
Street expected results to range from -49 cents to -46 cents per
share.
    * Revenue fell 21.1% to $3.24 million from a year ago;
analysts
expected $2.50 million. 
    * Aligos Therapeutics Inc's reported EPS for the quarter was
a
loss of 41 cents​.
    * The company reported a quarterly loss of $18.04 million.
    * Aligos Therapeutics Inc shares had risen by 0.4% this
quarter and lost 21.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 2.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for Aligos
Therapeutics Inc is $3.00 
This summary was machine generated from LSEG data November 2 at
11:18 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.47          -0.41          Beat
 Jun. 30 2023      -0.49          -0.43          Beat
 Mar. 31 2023      -0.48          -0.53          Missed
 Dec. 31 2022      -0.47          -0.51          Missed